Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yes they of course C11 ! They will attend. Hopefully less under the radar as more clinical data is released . Excellent interim’s have presentations to healthcare analysts . With conference season hopefully more keynote speaking opportunities. With a larger marketing budget to send more beefed up management to network.
It’s not just either or . It’s all a big picture. All involved, management, scientists, patients, advisers,patent expertise to protect Ip and shareholders with patient understanding , who having had their experts go the due diligence and deep enough pockets to sit wait and advise. Good luck to all
Thanks for your excellent post and observations TF , imagine last years melanoma conference may have given hope to patients and helped with recruitment into the trial ,
did anyone observe on the you tube link did Sarah mentions Poulam had also been presenting prior to her ?
with reference to
"how can price sensitive data be withheld from Shareholders until the opportunity arises such as AACR or ASCO, where 'previously unpublished data' is a requirement"
Hopefully there time to impress and excplaining ground breaking , trailblazing , scientific in scientific posters, in large halls is diminishing !
with a beefed up management and new PR team , its time to let the general media and business world in first the success in patients trials to address the derisory share price ?
Would welcome views on this ?
For Balance observations of Bermuda shorts post from the other board around. 3,30pm
a charity event focused event and presenting on current Melanoma trials is relevant. To give confidence to patients an informed choice and user friendly basis of what is happening on the trial front . Especially as recruitment and patient and physician awareness for the Scope trial , ensure big pharma had the data and numbers . The fact Sarah Danson is involved in at least 5 other trials.! Don’t view this negatively. Have no doubt she is experienced oncology presenter . Also have confidence that the Scancell data being presented will stand up next to its peers
I do however agree it’s obvious any new SCIB1 data will be presented by either Poulam or Lindy
Bermuda shorts full post from the other board around. 3,30pm
bermudashorts: Sorry, I know this won't be popular but I disagree. Sarah Danson is currently involved as investigator in at least 5 other active melanoma trials in addition to SCOPE and I'm sure she'll give an overview of those as well as other promising studies. However, any new SCIB1 results would be presented either by Lindy Durrant or Poulam Patel as PI at a more high profile scientific conference rather than a study investigator at a charity patient conference
Melanoma Patient Conference 2024
Thursday 29th February – Friday 1st March, 2024
Location: Voco St Johns Hotel, Solihull, Birmingham, B91 1AT
https://melanomafocus.org/support/meetings-and-events/melanoma-patient-conference-2024/
09:25am - 10:55am SESSION ONE: Updates in Melanoma Medicine
Chair: Imogen Cheese
09:25am - 09:55am Clinical Trials Update. Innovation and Progress (Professor Sarah Danson)
The clinical trails update is important and will be interesting, because
Prof Sarah Danson , was listed as an author on the poster presented in November 2023 SCOPE trial to be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/2023/231031-scancell-sitc-conference-.pdf
Poster presentation title A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab
+ ipilimumab in patients with advanced unresectable melanoma: Efficacy and
safety results from the open-label Phase 2 SCOPE trial
Authors Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson,
Martin Highley, Clare Barlow, Robert Miller, Fayaz Master and Lindy Durrant
Abstract number 1533
Session date and time Friday, Nov. 3, 2023, 9am – 7pm EDT
Location Exhibit Halls A and B1 – San Diego Convention Center
Also listed as investigator at the Modify tirial
Principal Investigator Prof Sarah Danson at
Cancer Clinical Trials Centre
Weston Park Cancer Centre
Whitham Road
Sheffield
S10 2SJ
https://modi-1-study.digitrial.com/locations/sheffield-teaching-hospital-nhs-foundation-trust/
Previously in 2022 you tube link from Sarah Danson
https://www.youtube.com/watch?v=ZaLLQmjnYuQ
21 mins in Scope trial explained
Don’t think for one moment the king will be going down homeopathic medicine route to test his cancer .Professor Angus Dalgleish has spoken out in several publications. On the matter of catching the cancer early
https://www.birminghammail.co.uk/news/midlands-news/king-charles-cancer-eminently-treatable-28577526.amp
Prominent British oncologist Professor Angus Dalgleish says the cancer is likely to be “eminently treatable”. Prof Dalgleish said while he would not want to speculate on the type of cancer the King has, he believed it sounded like “a very early cancer”.
Dr Micheal Dixon and cancer
A statement from the palace at the time of his appointment read: 'Dr Dixon does not believe homeopathy can cure cancer.”
https://en.m.wikipedia.org/wiki/Michael_Dixon_(doctor)
https://www.dailymail.co.uk/news/article-13048741/amp/King-Charles-expert-team-doctors-shepherd-treatment-unknown-cancer-monarch-said-wholly-positive-treatment.html
“ A statement from the palace at the time of his appointment read: 'Dr Dixon does not believe homeopathy can cure cancer.”
Reminder of Vulpes document on Scancell
“Multiple arrows in the quiver “
Author: Jamshed Dadabhoy
Date: April 17, 2023
My Observation all the issues of stronger management , more focused on commercial success has been achieved
Well funded to got it alone on the focused pipeline
Just need to sort the “We view the current share price as derisory” ?
Also there has been much good new data , since this report was published
https://vulpesinvest.com/life-sciences/scancell-holdings-plc-multiple-arrows-in-its-quiver/
Valuation: We view the current share price as derisory; reflective of poor market sentiment for biotech stocks and the early-stage nature of the business, with management too focused on the science, rather than medium- and long-term commercial aspects. If Modi 1 were successful across all 4 tumour indications, it could deliver c.$2.8bn in aggregate profits (present – value adjusted, but not probability adjusted) based on our (Vulpes) estimates. Even adjusted with a 10% PoS (probability of success) that would imply a market value of c.$280m – a c.62% uptick vis-à-vis the current market cap of around $173m. And this is from a single asset. Modi-2, which addresses other solid tumours like colorectal cancer, non-small cell lung cancer, and prostate cancer, among others, could (if successful across all indications) deliver c.$2.3bn in profits (our estimates; present – value adjusted, but not probability adjusted). Even adjusted with a 7% PoS that would imply a market value of c.$160m – which again equates to almost the entire current market capitalisation of the company.
2 interesting article, both have same quote from David Pinato .
also there is an assessment of the Race stating the Moderna and partner MSD are head of Biontech
I know Scancell is a DNA vaccine , however seem to be ahead , views please
also wondering where this leaves the personalised Moderna / Merck melanoma vaccine Partnership ?
wondering if Merck see another partnership as being quicker to market ? Especially after todays appointment
https://www.clinicaltrialsarena.com/news/imperial-college-cancer-therapy-trial/?cf-view&cf-closed
https://pharmaphorum.com/news/first-patient-treated-modernas-pd-1ido1-cancer-shot
Moderna and partner MSD have already advanced one mRNA vaccine called mRNA-4157 (also V940) into phase 3 trials alongside Keytruda in NSCLC and melanoma, used as an adjuvant therapy for earlier-stage tumours that can be treated with surgery. Results are due from 2029 onwards.
The partners seem to be a little ahead of BioNTech – Moderna’s arch-rival in the COVID-19 vaccine category – when it comes to applying the technology to cancer. BioNTech is also developing its BNT111 vaccine for relapsed/refractory melanoma that is in mid-stage testing in combination with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab), with results due next year.
Both articles have the same quote from David Pinato
Dr David Pinato said: “New mRNA-based cancer immunotherapies, such as mRNA-4359, offer a new avenue for recruiting the patient’s own immune system to fight their cancer.
“This research is still in the early stages and may be a number of years from being available to patients, but this trial is laying crucial groundwork that is moving us closer towards new therapies that are potentially less toxic and more precise. We desperately need these to turn the tide against cancer.”
Pinato is the investigator of the UK arm of this trial.
Thanks Jonny B for that link the Shropshire post
Compare and contrast of quotes on cancer Vaccinesdr David Pinato
On the 21st of February 2023, RNS on the data of the Modi trial.
l.
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/modify-efficacy-data-final-20.02.23.pdf
“Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial”
On the 21st of February 2023, RNS on the data of the Modi trial. Thought it would be interesting tosee what David Pinto said in view of the recent article that appeared in the Sunday papers with the (off-the-shelf) cancer vaccine Moderna say is in trial.
Dr David Pinato, Principal Investigator at Imperial College, commented: “Advanced ovarian cancer is an
aggressive cancer which is hard to treat. The early efficacy data showing that the Modi-1 vaccine is stabilising
this advanced disease is very encouraging”.
Prof Christian Ottensmeier, Chief Investigator, University of Liverpool commented: “The strong DTH
responses in all patients and the early clinical results, particularly in the patient with advanced SCCHN,
suggests that this therapeutic cancer vaccine could have significant potential. Further studies with Modi-1
monotherapy and in combination with CPIs should tell us in which settings it will have maximum benefit to
patients.
”
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “We are highly encouraged with the
early efficacy data we have achieved in the ModiFY clinical trial, and safety profile to date with patients
receiving Modi-1. These results allow us to proceed with the monotherapy expansion cohorts and into the
cohorts in combination with checkpoint inhibitors as planned.
”
Now what David Pinato was quoted
Thanks Johnny B for this post yesterday
https://www.shropshirestar.com/news/uk-news/2024/02/04/new-mrna-cancer-vaccine-from-moderna-trialled-in-british-patients/
This is part of what David Pinato says (This is all copied from the above link):-
He said the vaccine being tested in the trial is an “off-the-shelf vaccine” rather than one that is tailored to each individual patient.
While personalised vaccines can be very effective, they can take weeks to make and rely on a large tumour sample.
There is also not enough data at present to say whether personalised vaccines are in fact better than broader cancer vaccines, he said.
The Moderna vaccine, he added, is looking at specific traits across a number of tumours.
“It’s basically looking at what is the most frequent hit that you can target in cancer?,” he said.
“And so that has got incredible advantages in terms of the turnaround time, the fact you can make doses of the vaccines ahead of time even before meeting the patient. That is really the advantage.”
This paragraph sets out the ambitious road map scancell want to achieve
“I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in ..
I repeat “developing, registering, and commercialising novel biologics will be of great value to Scancell”
Three cheers
Wishing Sally Adams a healthy happy and wealthy retirement
Yes he is ! David Pinato is busy ?
In relation to Moderna vaccines in articles is it off the shelf . ? Also does it have the storage issues ? Couldn’t find more info !
More on this trial
the first link gives much more information ,
https://www.imperial.ac.uk/news/251213/first-uk-patients-receive-experimental-mrna/
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.TPS2676
WTP
This paper was procured 28th feb 2020 , with LD listed as an author , Scancell have come a long way since then
good luck to Richard Scolyer , what a good man
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594513/
Ray
Agree however, somebody mentioned that once the data starts to come in Biontech would not be able to afford it?
Does anybody recall Lindy mentioning the Moderna / Merck melanoma vaccine stating the ( Moderna)data was going to take quite a long time to come through?
Thinking out loud ! A personalised vaccine is likely to be long winded and an expensive trial?
The scope trial with improved additions and a new patent with CPI .
The Scancell data and the results will be coming through thick and fast , therefore there is no reason why the scope and Scancell will not beat Madonna to the race to being a fully developed approved vaccine brought to market at record speed ?
Sorry Sath
Excellent presentation , both Seth and Lindy looking very confident
Https://www.proactiveinvestors.co.uk/companies/news/1039647/scancell-geared-up-for-busy-2024-1039647.html
That said, its interim results statement showed Scancell to be in an enviable financial position compared with others in the industry in that it was sitting on £13.1 million as of 31 October 2023 (the end of the company's first half). The operating loss for the period was £8.1 million as Scancell invested heavily in developing its clinical assets.
The notable achievement in this period was "exceptional data" from the first stage of the SCOPE trial with SCIB1 showing an 85% objective response rate in 13 patients, exceeding Scancell's expectations of 70%.
Interesting
Merck's Keytruda extends life for kidney cancer patients after surgery, while Bristol's Opdivo fails again
https://www.fiercepharma.com/pharma/mercks-keytruda-extends-life-kidney-cancer-after-surgery-bristol-myers-opdivo-fails-again
Keytruda’s survival win comes just as Bristol Myers Squibb’s rival PD-1 inhibitor, Opdivo, failed for a second time in the same adjuvant kidney cancer setting, further consolidating Keytruda’s position as the only successful immunotherapy in the blockbuster market.
Roche ends KRAS deal with Hookipa Pharma, as biotech lays off 30% of staff
Interesting read ,
https://www.fiercebiotech.com/biotech/hookipa-reeling-roches-kras-cull-lays-30-workforce-deprioritizes-programs#:~:text=Roche%20has%20waved%20goodbye%20to,slimmed%2Ddown%20list%20of%20candidates.
Wishful thinking
What about a 50/50 partnership with a big pharma. ( like I said Moderna boasts, Merck stays quietly watching? ) Moving forward to stage 3 , approval , manufacture, ( LD said looking for a new one ? ) . Then binging to market and distribution. Fast track approval will be easier with a big pharma ?
Why not ? Life extension for cpi using Avidimab ? License deal
Evaluation by cell pharma maybe complete?
Does anyone consider a partnership in any of the trials with the relevant large pharma CPI? With Avidimab added? Extension to patent ?